Saturday, 6 September 2008
News From The Journal Of The National Cancer Institute, August 26 2008
Researchers propose a novel multi-arm trial plan that stool test various therapies simultaneously and could speed drug development in cancer.
Scientists experience gained significant insights into the biological underpinnings of cancer, merely this knowledge has non led to a leap out in the number of therapies sanctioned for clinical use. One possible ground for the slower than expected progress is the time required for clinical testing with current visitation designs.
With that issue in mind, Mahesh Parmar, Ph.D., of the Medical Research Council Clinical Trials Unit in London and colleagues modified banner clinical trial methodology so that multiple therapies or combinations lav be compared in a single trial. The new design incorporates standard phase II and phase III goals into one multiphase trial and requires fewer patients than standard trials.
In the comment, Parmar and colleagues talk about the want for fresh approaches to clinical trials, describe the new trial design in detail, and provide examples of on-going trials that use the multi-arm trial approach. "With three real examples, we hope that we get shown that such trials are practicable and commode lead to major improvements in speeding and determination making," the authors write.
Natural Chemical from Sea Sponges Induces Death in Cancer Cells via Unusual Pathway
A chemical called candidaspongiolide (CAN) inhibits protein synthesis simply also kills cancer cells by triggering caspase 12-dependent programmed cell death.
Previous reports showed that CAN preferentially killed glioma and melanoma cells in vitro, only its chemical mechanism of action was unknown.
In the electric current study, Giovanni Melillo, M.D., of the National Cancer Institute in Frederick, Md., and colleagues used molecular and cell assays to uncover the mechanism by which CAN kills cancer cells in vitro.
CAN halts protein synthesis in both normal and cancer cells but does not kill normal cells at dosages that induction cell death in the malignant cells. CAN induces cell decease by activation caspase 12 by an unusual biochemical pathway.
The investigators conclude that further tests with CAN are warranted in vitro and in animal models.
Deletion of Chromatin Remodeling Genes Leads to Leukemia in Mice
Mice deficient both copies of the Arid4A gene and one copy of the Arid4B gene develop acute myeloid leukemia (AML) and may provide an important animate being model for preleukemic and leukemic conditions.
It is well known that genetic mutations, which spay the sequence of DNA in chromosomes, can lead story to cancer. More late, researchers take found that changes in chromatin structure and activity (epigenetic changes) can lead to crab as well. The Arid4 family of genes is involved in chromosome remodeling, but their impact on leukemia was not known.
Arthur Beaudet, M.D., of Baylor College of Medicine in Houston and colleagues bred mice that lacked both copies of Arid4A and one copy of Arid4B. They monitored the animals' health through and through repeated blood cell counts and molecular tests on blood and bone bone marrow cells.
The variation mice developed a myeloproliferative disorder that resembled chronic myeloid-monocytic leukemia. The animals then progressed to AML. The pattern of disease progression in the animals resembled the course of events in humans and may indicate that the mutant mice are utilitarian models for studying how AML develops and testing potential therapeutics.
"Further study of the Arid4 gene family may advance our sympathy of the connection 'tween gene regulation, epigenetic ascendency, disease growing, and cancer formation," the authors write. "We too suggest that gene regulating by the ARID4A and ARID4B should be examined for potentiality disease-related roles, not only in human malignancies, simply also in other complex disease traits."
Mutations in the Succinate Dehydrogenase Subunit B Gene Associated with Familial Renal Cell Cancer
Individuals world Health Organization have a germline mutant in the succinate dehydrogenase subunit B (SDHB) factor presented with familial nephritic cell genus Cancer (RCC) or with bilateral RCC.
Previous inquiry suggested that germline mutations in succinate dehydrogenase genes were principally associated with the development of pheochromocytoma or paraganglioma, which are tumor syndromes that regard other tissues. Although RCC had been reported occasionally in individuals with a germline SDHB mutation, these individuals had a personal or fellowship history of pheochromocytoma or paraganglioma. Therefore, the association of mutations in succinate dehydrogenase genes with familial RCC in the absence of other tumor syndromes was unknown.
In the current study, Eamonn Maher, M.D., of the University of Birmingham in the UK and colleagues sequenced the genes encryption several of these enzymes in 68 individuals wHO had either familial RCC or bilateral RCC but who showed no evidence of phaeochromocytoma or paraganglioma.
They identified ternary individuals with germline mutations in SDHB in this population. They conclude that the mutations are associated with an increased risk of genetic RCC.
"Our findings suggest that individuals presenting with features of hereditary RCC susceptibility should be screened for germ�line SDHB mutations because surveillance for SDHB-related tumors can then be offered to mutation-positive patients and relatives," the authors write.
In an ensuant editorial, Charis Eng, M.D., Ph.D., of the Cleveland Clinic in Ohio notes that the new data confirm premature reports of an connexion between mutations in the SDHB factor and familial RCC. She thinks, however, that it is too early to conclude whether such mutations occur in the absence of tumour syndromes granted the relatively young age at which the ternary patients in Maher's study either died or were lost to follow-up and the later age of onset for pheochromocytoma or paraganglioma.
Nonetheless, the new information have clinical utility, according to Eng. "It is entirely appropriate, at this time, to counsel patients carrying SDHB mutations, espe�cially those with Arg mutations, that they have a small simply finite likelihood of development RCC," she writes.
Also in the August 26 JNCI:
* hTTP://www.eurekalert.
Wednesday, 27 August 2008
Jack White Discusses James Bond Song
Jack White has discussed the song 'Another Way To Die', which he recorded with singer Alicia Keys for the forthcoming James Bond movie 'Quantum Of Solace', which is released in October.
"After a couple of years of wanting to collaborate with Alicia Keys, it took James Bond himself to finally hold it happen." The White Stripes ballad maker says in a statement. "Alicia place some electrical energy into her breath that cemented itself into the magnetic tape. Very inspiring to watch."
"I drummed for her voice and she mimicked the guitar tones, then we joined our voices and screamed and moaned about these characters in the cinema and their isolation, having no-one to trust, non even themselves. Maybe we became them for a few minutes."
Jack also added he was inspired by the retro recordings of previous Bond themes: "It might be the low gear analogue Bond theme in 20 age. We cherished to press soul into those tapes and join the family unit of Barry, Bassey, Connery and Craig."
More info
Thursday, 7 August 2008
Level 3
Artist: Level 3
Genre(s):
Drum & Bass
Discography:
Contamination / Living Machine
Year: 1997
Tracks: 2
 
Tuesday, 1 July 2008
Ringo Starr sells personal art collection
.adlinks{font-family:arial;font-size:12px;color:#ffffff !important;line-height:19px;background-color: #F47321;}
Wednesday, 25 June 2008
Mac Mall
Artist: Mac Mall
Genre(s):
Rap: Hip-Hop
Discography:
Da U.S. Open
Year: 2005
Tracks: 12
Mackin Speaks Louder Than Words
Year: 2002
Tracks: 15
Along with better-known rappers like E-40 and 2Pac, Mac Mall was one of several wHO helped put the Cali Bay Area on the map in the mid to late '90s as a hotspot in the rap game. He collaborated with many of the Bay Area's best producers -- Ant Banks, Khayree, Michael Mosley, and Rick Rock -- and helped define the scene's personal identity, in particular with his almost successful record album, Untouchable (1996), which featured perchance his best-known strain, "Become Right." His career simmered out promptly, nonetheless. He returned in 1999 subsequently a three-year absence and few listeners seemed to notice. Mall was no longer on a major label and the Bay Area fit was no thirster the hotspot it had been a few long time originally. Given his brief moment in the public eye and his sudden decline, it was peradventure no surprise when Mall changed his style in 2001, incorporating a surprising sum of money of spiritualism on his Immaculate album.
Friday, 13 June 2008
Lee Not About To Shut His Face
See Also
Saturday, 7 June 2008
Phobia
Artist: Phobia
Genre(s):
Drum & Bass
Metal: Death,Black
Rock: Grindcore
Rock
Soundtrack
Discography:
All Points North EP
Year: 2006
Tracks: 2
Renegade (RR62)
Year: 2005
Tracks: 2
Is It True Vinyl
Year: 2005
Tracks: 2
Get Up and Kill
Year: 2004
Tracks: 17
Grind Your Fucking Head In
Year: 2003
Tracks: 17
Critical
Year: 2003
Tracks: 2
Serenity Through Pain
Year: 2001
Tracks: 23
Means Of Existence
Year: 1998
Tracks: 17
Return To Desolation
Year: 1994
Tracks: 8